<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372096">
  <stage>Registered</stage>
  <submitdate>5/01/2017</submitdate>
  <approvaldate>11/01/2017</approvaldate>
  <actrnumber>ACTRN12617000050358</actrnumber>
  <trial_identification>
    <studytitle>Australian and New Zealand Lymphoma and Related Diseases Registry </studytitle>
    <scientifictitle>Australian and New Zealand Lymphoma and Related Diseases Registry</scientifictitle>
    <utrn />
    <trialacronym>LaRDR</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a patient Registry collecting information on patients with a new diagnosis of non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukaemia and related diseases. Information will be collected by review of medical records.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival which is assessed by review of hospital records.


</outcome>
      <timepoint>two years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of life which is assessed using the EQ-5D-5L questionnaire</outcome>
      <timepoint>two years
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to disease progression which is assessed by review of hospital records.</outcome>
      <timepoint>Two years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with a new diagnosis of non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukaemia and related diseases. Diagnosis within 6 months prior to HREC approval at the site, in order to minimise retrospective data collection.
Age 18 years or older
Cause of death listed as lymphoma.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who have chosen to opt-off the registry. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Analysis plans will be reviewed by the Steering Committee and by a suitably qualified statistician prior to data from the LaRDR being analysed.
A detailed pre-determined statistical plan will be developed prior to planned analyses of registry data.  </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>True</patientregistry>
    <followup>24</followup>
    <followuptype>Months</followuptype>
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>17/08/2016</actualstartdate>
    <anticipatedenddate>31/12/2020</anticipatedenddate>
    <actualenddate />
    <samplesize>3000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,WA,VIC</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <hospital>Concord Private Hospital - Concord</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>The Canberra Hospital - Garran</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>2137 - Concord</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>2605 - Garran</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Wellington Road
Clayton, Victoria, 3800

</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Takeda Pharmaceuticals Australia Pty Ltd</fundingname>
      <fundingaddress>Ground Floor
2-4 Lyon Park Rd
MACQUARIE PARK  NSW  2113
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche Products Pty Ltd</fundingname>
      <fundingaddress>4-10 Inman Road
Dee Why, NSW, 2099</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Celgene Pty Limited</fundingname>
      <fundingaddress>Level 7, 607 St Kilda Rd,
 Melbourne VIC 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol-Myers Squibb Australia Pty Ltd</fundingname>
      <fundingaddress>Level 2,
4 Nexus Court
Mulgrave, Victoria, 3170</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Janssen-Cilag Pty Ltd</fundingname>
      <fundingaddress>1-5 Khartoum Road
Macquarie Park NSW 2113
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals Australia Pty Ltd</fundingname>
      <fundingaddress>54 Waterloo Road 
Macquarie Park, NSW, 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to provide long-term patient follow-up, and review of clinical and correlative data outside of clinical trials.

Who is it for?
The registry will collect information on patients age 18 years or older, with a new diagnosis of non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukaemia and related diseases. 

Study details
Treating clinicians at sites will identify patients at the time of referral and enrol them to the study. The following categories of data items will be collected to the LaRDR database using a web portal:
Demographic details
Health at diagnosis
Laboratory and imaging results at diagnosis
Therapy decisions, including pre-therapy benchmarking, chemotherapy, autologous and allogeneic stem cell transplantation, and maintenance and supportive therapies
Outcomes including (survival and QoL measures.

It is hoped that the findings from this study will identify patterns of treatment and variation in outcomes, for survival and quality of life. Findings will be valuable in informing optimal treatment strategies for lymphoid cancers and assist with evaluation of the translation of advances in therapies outside the setting of clinical trials.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash Health HREC</ethicname>
      <ethicaddress>Monash Medical Centre
246 Clayton Road
Clayton, Victoria, 3168</ethicaddress>
      <ethicapprovaldate>1/07/2016</ethicapprovaldate>
      <hrec>HREC/16/MonH/74</hrec>
      <ethicsubmitdate>5/05/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Erica Wood</name>
      <address>Monash University
Department of Epidemiology and Preventive Medicine
The Alfred Centre
99 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 99030051</phone>
      <fax />
      <email>erica.wood@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Zoe McQuilten</name>
      <address>Monash University
Department of Epidemiology and Preventive Medicine
The Alfred Centre
99 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 99030379</phone>
      <fax />
      <email>zoe.mcquilten@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Zoe McQuilten</name>
      <address>Monash University
Department of Epidemiology and Preventive Medicine
The Alfred Centre
99 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 99030379</phone>
      <fax />
      <email>zoe.mcquilten@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Neil Waters</name>
      <address>Monash University
Department of Epidemiology and Preventive Medicine
The Alfred Centre
99 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 99030407</phone>
      <fax />
      <email>neil.waters@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>